SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Experimental Anti-ObesityResearch peptide

Adipotide

aka FTPP

Pro-apoptotic peptide that targets the vasculature of white adipose tissue in preclinical work.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Adipotide is a fusion peptide combining a homing motif for white adipose vasculature with a pro-apoptotic sequence, studied as an experimental anti-obesity agent.

Source
  • Synthesized in research settings
Forms
  • Subcutaneous injection (research)

Mechanism of action

Binds prohibitin on white adipose endothelium and triggers apoptosis of the supporting vasculature, leading to localized fat tissue loss.

Pathways
  • · Prohibitin homing
  • · Endothelial apoptosis
  • · Adipose tissue regression

How it acts on the body

Adipotide was designed to test whether targeting the blood supply of adipose tissue could shrink fat depots without the side effects of central appetite-acting drugs. In obese rhesus monkeys it produced substantial weight loss and reduced adiposity over weeks.

Serious concern: nephrotoxicity, related to the proximal tubule's high uptake of small cationic peptides, halted enthusiasm for systemic human use. Current interest is largely academic and focused on safer targeting strategies.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Adipose-derived hormonesDecreases
Leptin and adiponectin fall as adipose mass regresses.
Insulin sensitivityModulates
Improvement reported in primate studies.

Effects on the body

Decreases
White adipose tissue mass in primates
Decreases
Body weight without affecting appetite centrally

Organ system effects

Skin

Primary target — vasculature pruning leads to regression.

Kidneys

Significant toxicity signal limiting development.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Peripheral mechanism, no central appetite effect
  • Novel target — adipose vasculature

Potential side effects

Common
  • · Limited human data
Rare
    Serious
    • · Nephrotoxicity (proximal tubule injury) — the major reason it has not advanced clinically

    Drug interactions

    Nephrotoxic agents
    Additive renal injury concern.
    moderate

    Pairing context

    Often combined with
    • Nothing in clinical use — pre-clinical only
      Not appropriate for human application at this time.
    Avoid combining with
    • Any chronic kidney disease
      Nephrotoxicity risk is the dose-limiting toxicity.
    Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.